RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000131.xml
Synfacts 2011(8): 0811-0811
DOI: 10.1055/s-0030-1260677
DOI: 10.1055/s-0030-1260677
Synthesis of Natural Products and Potential Drugs
© Georg Thieme Verlag
Stuttgart ˙ New York
Synthesis of Carmegliptin
Rezensent(en):Philip KocienskiS. Abrecht, J.-M. Adam, U. Bromberger, R. Diodone, A. Fettes*, R. Fischer, V. Goeckel, S. Hildbrand, G. Moine, M. Weber
F. Hoffmann-La Roche Ltd., Basel, Switzerland
An Efficient Process for the Manufacture of Carmegliptin
Org. Process Res. Dev. 2011, 15: 503-514
F. Hoffmann-La Roche Ltd., Basel, Switzerland
An Efficient Process for the Manufacture of Carmegliptin
Org. Process Res. Dev. 2011, 15: 503-514
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
20. Juli 2011 (online)
Key words
carmegliptin - DPP-4 inhibitors - Mannich reaction - crystallization-induced dynamic resolution - Hofmann rearrangement
Significance
Carmegliptin is a dipeptidyl dipeptidase-IV inhibitor under development for the treatment of type-2 diabetes. Over 1000 kg was synthesized by the route depicted featuring an efficient crystallization-induced dynamic resolution of rac-D and a large-scale Hofmann rearrangement of the amide F.
Comment
J.-M. Adam et al. (Org. Process Res. Dev. 2011, 15, 515) describe the synthesis of lactone H by asymmetric hydrogenation (10 kg scale), but a route starting from commercial (S)-tert-butyl glycidyl ether (derived from a Jacobsen hydrolytic kinetic resolution) delivered >500 kg of H.